Product
Resveratrol
10 clinical trials
11 indications
Indication
Chronic Obstructive Pulmonary DiseaseIndication
Cystic FibrosisIndication
Diabetic NeuropathyIndication
Mitochondrial FunctionIndication
Physical FunctionIndication
Peripheral Artery DiseaseIndication
COVID-19Indication
Diabetic NeuropathiesIndication
LymphangioleiomyomatosisIndication
Type 1 DiabetesIndication
Friedreich AtaxiaClinical trial
Improving Cardiovascular Health in Patients With Chronic Obstructive Pulmonary Disease: a Mechanistic ApproachStatus: Completed, Estimated PCD: 2022-08-30
Clinical trial
Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic FibrosisStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Assessment of Resveratrol, Alpha Lipoic Acid and Superoxide Dismutase on Oxidative Stress Biomarkers in Type 2 Diabetes Mellitus Patients With Neuropathy: A Randomized Control TrialStatus: Active (not recruiting), Estimated PCD: 2023-12-22
Clinical trial
Phase IIa Study of Resveratrol to Enhance Mitochondrial and Physical Function in Older AdultsStatus: Completed, Estimated PCD: 2019-05-02
Clinical trial
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease: The NICE TrialStatus: Completed, Estimated PCD: 2023-05-23
Clinical trial
Randomized Double-Blind Placebo-Controlled Proof-of-Concept Trial of Resveratrol, a Plant Polyphenol, for the Outpatient Treatment of Mild Coronavirus Disease (COVID-19)Status: Terminated, Estimated PCD: 2021-03-01
Clinical trial
Impact of Resveratrol and Pharmaceutical Care on Diabetes Mellitus and Its Neuropathic ComplicationStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)Status: Completed, Estimated PCD: 2022-10-15
Clinical trial
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Randomised Placebo-controlled Crossover Trial of Micronised Resveratrol as a Treatment for Friedreich AtaxiaStatus: Completed, Estimated PCD: 2024-03-28